Agreement Announcement by President Trump

On October 10, 2025, President Donald J. Trump announced a new agreement with AstraZeneca to implement most-favored-nation pricing for American patients. This agreement allows every state Medicaid program to access lower drug prices, leading to significant savings for American patients, especially those with chronic conditions like asthma and COPD. The deal includes discounts on specific inhalers and ensures that AstraZeneca will return increased foreign revenues to benefit U.S. patients.

This agreement is a notable advancement in the Trump Administration’s efforts to tackle disparities in pharmaceutical pricing between the United States and other developed countries. AstraZeneca will invest $50 billion in U.S. manufacturing and research by 2030, which is projected to create around 3,600 skilled jobs in Virginia. This initiative aims to enhance the domestic pharmaceutical supply chain and decrease reliance on foreign production.

Additionally, President Trump highlighted the need to prevent American taxpayers from subsidizing drug prices abroad while facing higher costs domestically. These actions are part of a broader strategy to reduce prescription drug prices in the U.S. and ensure that Americans have access to affordable medications. The Administration is dedicated to reforming the pharmaceutical pricing system to improve the affordability and accessibility of healthcare for American families.

Original: article